AstraZeneca PLC (AZN.L)
3,155.00GBp
6:33am EDT
4.00p (+0.13%)
3,151.00p
3,159.00p
3,163.50p
3,139.50p
290,553
2,292,701
3,544.50p
2,786.00p
AZN.L
About
Overall
| Beta: | 0.39 |
| Market Cap (Mil.): | £39,437.75 |
| Shares Outstanding (Mil.): | 1,252.09 |
| Dividend: | 122.26 |
| Yield (%): | 5.72 |
Financials
| AZN.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 10.61 | 32.92 | 33.02 |
| EPS (TTM): | 2.97 | -- | -- |
| ROI: | 15.60 | 19.76 | 19.07 |
| ROE: | 25.88 | 20.57 | 20.00 |
Fitch Downgrades Bristol Myers Squibb's IDR to 'A-'; Outlook to Stable
(The following statement was released by the rating agency) CHICAGO, July 01 (Fitch) Fitch Ratings has downgraded Bristol-Myers Squibb Co.'s (Bristol Myers Squibb) long-term Issuer Default Rating (IDR) to 'A-' from 'A'. See a full list of affected ratings below. The ratings apply to approximately $7.3 billion of debt. The Rating Outlook is revised to Stable from Negative. KEY RATING DRIVERS --Operational pressure peaking in 2013: Plavix and Avapro patent expirations have negatively affect
UPDATE 2-Astra, Bristol diabetes drug disappoints in key test
LONDON, June 19 - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.
AstraZeneca, Bristol diabetes drug disappoints in key test
LONDON - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.
AstraZeneca, Bristol diabetes drug fails to show heart benefit
LONDON, June 19 - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study.
AstraZeneca turnaround is 3-4 year journey, says CEO
LONDON - Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday.
REFILE-UPDATE 1-AstraZeneca picks site for new global home in Cambridge
* Cambridge Biomedical Campus to house new HQ and R&D centre
AstraZeneca picks site for new global home in Cambridge
LONDON - AstraZeneca has chosen a science park on the southern outskirts of Cambridge, England, next to the world-renowned Addenbrooke's Hospital, for its new $500 million global headquarters and research center.
AstraZeneca picks its new home in Cambridge next to top hospital
LONDON, June 18 - AstraZeneca has chosen a science park in Cambridge, England, next to the world-renowned Addenbrooke's Hospital, as its new $500 million global headquarters and centre of drug research.
BRIEF-AstraZeneca's MedImmune, NGM Biopharmaceuticals in deal to develop therapies for diabetes and obesity
LONDON, June 17 - AstraZeneca PLC : * Medimmune,NGM Biopharmaceuticals announce agreement to discover and develop
AstraZeneca taps outside experts to screen cancer compounds
LONDON, June 14 - British drugmaker AstraZeneca is deepening its collaboration with academia by roping in more outside researchers to help to find new cancer drugs.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
